Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2011

View Archived Issues

Yale University scientists synthesize the aglycon of lomaiviticin A, a promising anticancer agent

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Medivir begins phase Ia trial of HCV polymerase inhibitor TMC-649128

Bombesin BB2 receptor antagonist 77427 shows promise in preclinical models of asthma

Gap junction alpha-1 protein is a marker of prognosis in prostate cancer

First-in-class antibiotic RNPA-1000 inhibits bacterial turnover of RNA

Genotype of polymorphic SLC6A4 gene variants modulates effects of cocaine in vitro

Endoribonuclease Dicer is a potential target for geographic atrophy

New neuraminidase inhibitors claimed at University of British Columbia

AtheroNova advances preclinical evaluation of agents for atherosclerosis

Astellas Pharma withdraws MAA for darexaban in Japan

Adventrx to acquire SynthRx and purified poloxamer-188 for sickle cell disease

SYGNIS Pharma licenses European patent rights to AX-200

Crofelemer is safe and efficacious in phase II trial in adults with watery diarrhea

Lymphoseek phase III trial in breast cancer and melanoma reaches accrual objective

Australian scientists claim novel inhibitors of neuraminidase

Apricus licenses Vitaros to Neopharm in Israel and Palestinian territories

Alkermes reports phase II data on ALKS-37 in opioid-induced bowel dysfunction

Lundbeck donates certain rights regarding Lu-AE58479 to NINDS

New inhibitors claimed of MEKK 5

FDA accepts Acurox NDA filing and grants priority review

Sanofi-aventis to acquire Genzyme

Treatment begins in phase III trial of rHuPH20-delivered MabThera in NHL

FDA requests additional development activities to support approval of Adventrx's ANX-514

Raptor Pharma reopens enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...